S. Malhan Et Al. , "DAPAGLIFLOZIN VERSUS A DIPEPTIDYL PEPTIDASE 4 INHIBITOR (DPP4) BOTH ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM): IMPACT ON HEALTH, QUALITY OF LIFE AND COSTS IN THE TURKISH CLINICAL SETTING," VALUE IN HEALTH , vol.18, no.7, 2015
Malhan, S. Et Al. 2015. DAPAGLIFLOZIN VERSUS A DIPEPTIDYL PEPTIDASE 4 INHIBITOR (DPP4) BOTH ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM): IMPACT ON HEALTH, QUALITY OF LIFE AND COSTS IN THE TURKISH CLINICAL SETTING. VALUE IN HEALTH , vol.18, no.7 .
Malhan, S., Guler, S., Yetkin, İ., Ignacio, T. J., Verheggen, B., & Charokopou, M., (2015). DAPAGLIFLOZIN VERSUS A DIPEPTIDYL PEPTIDASE 4 INHIBITOR (DPP4) BOTH ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM): IMPACT ON HEALTH, QUALITY OF LIFE AND COSTS IN THE TURKISH CLINICAL SETTING. VALUE IN HEALTH , vol.18, no.7.
Malhan, S. Et Al. "DAPAGLIFLOZIN VERSUS A DIPEPTIDYL PEPTIDASE 4 INHIBITOR (DPP4) BOTH ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM): IMPACT ON HEALTH, QUALITY OF LIFE AND COSTS IN THE TURKISH CLINICAL SETTING," VALUE IN HEALTH , vol.18, no.7, 2015
Malhan, S. Et Al. "DAPAGLIFLOZIN VERSUS A DIPEPTIDYL PEPTIDASE 4 INHIBITOR (DPP4) BOTH ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM): IMPACT ON HEALTH, QUALITY OF LIFE AND COSTS IN THE TURKISH CLINICAL SETTING." VALUE IN HEALTH , vol.18, no.7, 2015
Malhan, S. Et Al. (2015) . "DAPAGLIFLOZIN VERSUS A DIPEPTIDYL PEPTIDASE 4 INHIBITOR (DPP4) BOTH ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM): IMPACT ON HEALTH, QUALITY OF LIFE AND COSTS IN THE TURKISH CLINICAL SETTING." VALUE IN HEALTH , vol.18, no.7.
@article{article, author={S. Malhan Et Al. }, title={DAPAGLIFLOZIN VERSUS A DIPEPTIDYL PEPTIDASE 4 INHIBITOR (DPP4) BOTH ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM): IMPACT ON HEALTH, QUALITY OF LIFE AND COSTS IN THE TURKISH CLINICAL SETTING}, journal={VALUE IN HEALTH}, year=2015}